TipRanksStock Market NewsHRMY NewsRaymond James Believes Harmony Biosciences Holdings (HRMY) Won’t Stop Here

Raymond James Believes Harmony Biosciences Holdings (HRMY) Won’t Stop Here

Raymond James analyst Danielle Brill maintained a Buy rating on Harmony Biosciences Holdings (HRMYResearch Report) today and set a price target of $60.00. The company’s shares closed last Tuesday at $55.42, close to its 52-week high of $57.13.

According to TipRanks.com, Brill is a 5-star analyst with an average return of 12.7% and a 54.9% success rate. Brill covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Sarepta Therapeutics, and SAGE Therapeutics.

Currently, the analyst consensus on Harmony Biosciences Holdings is a Moderate Buy with an average price target of $60.50, representing an 11.6% upside. In a report issued on July 27, Mizuho Securities also maintained a Buy rating on the stock with a $64.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Harmony Biosciences Holdings’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $85.31 million and net profit of $21.49 million. In comparison, last year the company earned revenue of $59.67 million and had a net profit of $7.39 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs.

Read More on HRMY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More